A Long-term Study of AK102 in Patients With Hypercholesterolemia
Status:
Not yet recruiting
Trial end date:
2022-08-30
Target enrollment:
Participant gender:
Summary
This is a phase II, open-label, non-controlled, extended study. The main objective of this
study is to evaluate the long-term efficacy and safety of AK102 in combination with basic
lipid-lowering therapy in patients with hypercholesterolemia. Subjects who have participated
in the AK102 studies and have completed the last visit,and who, in the opinion of the
investigator, are likely to benefit from continued treatment will be enrolled in this study.